EQUITY RESEARCH Healthcare | European Pharmaceuticals | 23 July 2010 ACTELION To be or not to be a biotech company Initiating with a 1-Overweight rating – generic risk…

1. May 2012 CORTHOUGHTS …a slow-burningcollection ofstem celldisorders that have clinicians handcuffed when it comes toofferingmeaningfulinterventions. Myelofibrosis and…

Slide 1 JAK inhibitors update from ASH Claire Harrison Guy’s and St Thomas’ Hospitals London Slide 2 Slide 3 INCB18424 - Ruxolitinib – a JAK 1 and 2 inhibitor Structure…

INTRODUCTION Cancer: Exploding Treatment and Diagnostic Pipeline, and Ever-Increasing Costs Craig K. Deligdish, MD PERSPECTIVES Defining Value in Cancer Care: AVBCC 2012…

Sonographic Determination of Normal Spleen Size in Turkish Adults Determinación Ecográfica del Tamaño Normal del Bazo en Adultos Turcos Medih Çeliktas*;